Drug Resistance in Glioblastoma: A Mini Review |
| |
Authors: | Catherine?P?Haar Preetha?Hebbar IV" target="_blank">Gerald?C?WallaceIV Arabinda?Das III" target="_blank">William?A?VandergriftIII Joshua?A?Smith Pierre?Giglio Sunil?J?Patel Swapan?K?Ray Email author" target="_blank">Naren?L?BanikEmail author |
| |
Institution: | (1) Divisions of Neurology and Neurosurgery, Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA;(2) Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, USA |
| |
Abstract: | Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central nervous system cancer. Currently
used surgical techniques, chemotherapeutic agents, and radiotherapy strategies have done very little in extending the life
expectancies of patients diagnosed with GBM. The difficulty in treating this malignant disease lies both in its inherent complexity
and numerous mechanisms of drug resistance. In this review, we summarize several of the primary mechanisms of drug resistance.
We reviewed available published literature in the English language regarding drug resistance in glioblastoma. The reasons
for drug resistance in glioblastoma include drug efflux, hypoxic areas of tumor cells, cancer stem cells, DNA damage repair,
and miRNAs. Many potential therapies target these mechanisms, including a series of investigated alternative and plant-derived
agents. Future research and clinical trials in glioblastoma patients should pursue combination of therapies to help combat
drug resistance. The emerging new data on the potential of plant-derived therapeutics should also be closely considered and
further investigated. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|